CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 17 enrolled
Drug / intervention
Telmisartandrug
Likely dose
Telmisartan 80mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01578772
NCT01578772Phase 2Completed
CompareCT.gov

Telmisartan and Flow-Mediated Dilatation in Older HIV-Infected Patients at Risk for Cardiovascular Disease

University of California, Los Angeles·interventional·Posted Apr 17, 2012·Updated Dec 8, 2014

In Brief

A Phase 2 clinical trial evaluating Telmisartan for Endothelial Dysfunction. Completed, enrolled 17 participants across 1 site.

Detailed Summary

This research study is to see whether blood vessel function, an early sign of heart disease, improves in HIV-infected men and women who take telmisartan for 12 weeks. The investigators will be looking at how a blood vessel in the arm, called the brachial artery, changes in response to stress before and after taking telmisartan. To determine how well the blood vessel functions, the investigators will be using an ultrasound machine. Telmisartan is not an HIV medication. It is an FDA-approved medication designed to treat blood pressure, but has been shown to improve blood vessel function in HIV-negative people with and without high blood pressure. Telmisartan is made by Boehringer Ingelheim, and this trial is sponsored by The Campbell Foundation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndothelial Dysfunction
CountriesUnited States
CollaboratorsThe Campbell Foundation

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 17, 2012
Enrollment StartAug 1, 2012
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 14.2 years ago

Interventions

Telmisartandrug

80mg tablets po daily for 6 weeks